SEC Form 4 · accession 0001209191-16-111003

Corvus Pharmaceuticals, Inc. · CRVS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

A/S Novo

10% Owner

Period of report

Mar 29, 2016

Accepted (ET)

Mar 30, 2016 · 1:07 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001626971

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Mar 29, 2016	C	2,130,492	—	A	2,130,492	D
Common Stock^F1	Mar 29, 2016	C	356,888	—	A	2,487,380	D
Common Stock	Mar 29, 2016	P	666,666	$15.00	A	3,154,046	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F1	—	Mar 29, 2016	C	2,130,492	D	—	—	Common Stock	2,130,492	0	D
Series B Preferred Stock^F1	—	Mar 29, 2016	C	356,888	D	—	—	Common Stock	356,888	0	D

Explanation of responses

F1The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") had no expiration date. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.
F2Represents a purchase from the underwriters in the Issuer's public offering.

Remarks

Novo A/S is a Danish limited liability company. The board of directors of Novo A/S (the "Novo Board"), which is currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.